Research progress of early intervention in Crohn′s disease

Xuemei Jia,Jixiang Zhang,Shan Tian,Weiguo Dong

DOI: https://doi.org/10.3760/cma.j.issn.2096-367X.2019.03.017

2019-01-01

Abstract:This article reviews recent literatures regarding early intervention in Crohn′ s disease (CD) and summarizes its definition,benefits and risks. Furthermore,key points of research projects are proposed.

What problem does this paper attempt to address?

Advances in early diagnosis and treatment of Crohn's disease

Liang CHEN,Chun-Jin XU,Zhan-Ju LIU

DOI: https://doi.org/10.12173/j.issn.1004-5511.202206041

2022-01-01

New Medicine

Abstract:The early symptoms of Crohn’s disease（CD） are atypical and lacking in specificity so rendering early diagnosis of CD challenging. Therefore, improving the identification of early CD is conducive to early diagnosis and timely treatment, thus improving the prognosis of patients with CD and reducing the disability rate and associated disease burden. This paper reviews the research progress in developing early diagnostic biomarkers and targeted biotherapy for CD.
Research progress of early clinical diagnosis of Crohn′s disease

杨想,吴莺

DOI: https://doi.org/10.3760/cma.j.cn101480-20210511-00037

2022-01-01

Abstract:Crohn′s disease (CD) is a chronic recurrent inflammation of the digestive tract of unknown etiology. The incidence of CD is increasing year by year, but the early symptoms of CD are atypical and lack of specificity. Early diagnosis of CD is difficult, patients often see a doctor because of serious complications which makes the operation rate and disability rate of CD at a high level. Therefore, improving the understanding of the early clinical manifestations of CD and using the increase auxiliary examinations that help early diagnosis may increase early diagnosis rate. CD patients can receive timely treatment and have better efficacy, prognosis and quality of life. This article reviews the early clinical manifestations of CD and the auxiliary examinations that help early diagnosis of CD.
Anti-cytokine Therapy and Small Molecule Agents for the Treatment of Inflammatory Bowel Disease

Yuancong Jiang,Dan Kong,Xudong Miao,Xinmiao Yu,Zelai Wu,Han Liu,Weihua Gong

DOI: https://doi.org/10.1684/ecn.2021.0472

2021-01-01

European Cytokine Network

Abstract:Inflammatory bowel disease (IBD), including Crohn disease and ulcerative colitis, with multifactorial etiologies has led to a global health-associated burden in many countries. Substantial efforts are devoted to understand the pathogenesis, behavioral and environmental triggers, which may be specifically valuable for the treatment of IBD. The specific pathogenesis underlying IBD is as yet incompletely understood. The use of anti-cytokine therapy and small molecule agents targeting the immune system is thought to restore the body's intestinal barrier function and relieve inflammation with manageable adverse effects. In this review, we report recent advances in anti-cytokine therapy and treatment with small molecule agents for the management of IBD.
Research progress of metabonomics and nutritional intervention in Crohn's disease

夏凯,高仁元,陈春球,孙静,尹路

DOI: https://doi.org/10.3760/cma.j.cn115822-20210426-00094

2021-01-01

Abstract:Crohn's disease (CD) is a chronic nonspecific intestinal inflammatory disease with unclear etiology and pathogenesis. At present, it is believed that CD can cause different degrees of metabolic abnormalities, and that the related metabolites also play an important role in the development and progression of the disease. In recent years, metabonomics is becoming more and more well-developed and has provided guidance for clinicians on rational nutritional support. Here is a review on the metabolic changes of multiple systems in CD patients, the application of metabonomics in CD diagnosis and treatment, and the research progress of clinical nutrition intervention.
Research progress on acupuncture and moxibustion for treatment of Crohn's disease based on the regulation of innate immunity

Jing XIE,Wen-jia WANG,Yu-chao HOU,Ou-ping LIAO,Si-wei HUANG,Jia-jing LU,Hui-rong LIU,Yan HUANG,Jing LI,Huan-gan WU

DOI: https://doi.org/10.1016/j.wjam.2024.04.006

2024-04-01

World Journal of Acupuncture - Moxibustion

Abstract:Crohn's disease (CD) is an inflammatory bowel disease whose pathogenesis remains unclear. In this paper, we reviewed the basic research of acupuncture and moxibustion in treating CD by regulating intestinal intrinsic immunity, and summarized in more detail that acupuncture and moxibustion can regulate the intestinal intrinsic immune system through the intestinal epithelial cell barrier, monocytes/macrophages, natural killer cells (NK cells), dendritic cells (DC), and neutrophils. Specifically, acupuncture and moxibustion can reduce the expression of inflammatory factors in the intestinal mucosa, alleviate intestinal fibrosis to repair the mechanical barrier of the intestinal mucosa, inhibit the expression of molecules of the MAPK, TLR/NF-κB signaling pathway and inflammatory factors, block the NK cell-mediated cytotoxicity pathway, and prevent the overactivation of neutrophils to control inflammatory responses, repairing the damaged intestinal tract and alleviating CD symptoms. This paper illustrated the characteristics of acupuncture and moxibustion for CD, which involves multi targets and pathways, aiming to provide guidance for the clinical application and basic research of acupuncture and moxibustion for CD. It also pointed out the current drawbacks of acupuncture and moxibustion therapy, and finally proposing the shortcomings of the current research, including the insufficient number of studies on acupuncture and moxibustion in the treatment of CD through the modulation of NK cells and neutrophils, the lack of standardization in acupuncture point selection, duration and treatment course, and the geographical limitations of the research locations for acupuncture and moxibustion in treating CD.

integrative & complementary medicine
Pay Attention to Early Diagnosis and Management of Crohn’s Disease

Shirong LI

DOI: https://doi.org/10.3969/j.issn.1008-7125.2015.06.001

2015-01-01

Abstract:Crohn’s disease( CD)is a chronic,progressive and destructive intestinal inflammatory disease, frequently associated with tissue and functional damage in intestinal tract. There is no specific clinical feature at its early stage,30% ~ 50% of the patients are associated with various complications at the time of diagnosis and are quite difficult to cure. Opportunistic screening performed in high risk population is a valuable strategy for early finding(pre-lesion of CD) and early diagnosis( CD without complication). Colonoscopy and screening of serum and fecal markers might be the methods for early diagnosis. Early treatment may alter the natural history of the disease.
Efficacy of Early Intervention on the Bowel Damage and Intestinal Surgery of Crohn’s Disease, Based on the Lémann Index

Zhu Mingming,Feng Qi,Xu Xitao,Qiao Yuqi,Cui Zhe,Yan Yunqi,Ran Zhihua

DOI: https://doi.org/10.1186/s12876-020-01575-7

2020-01-01

BMC Gastroenterology

Abstract:Background : Clinicians aim to prevent progression of Crohn’s disease (CD); however, many patients require surgical resection because of cumulative bowel damage. The aim of this study was to evaluate the impact of early intervention on bowel damage in patients with CD using the Lémann Index and to identify bowel resection predictors. Methods : We analyzed consecutive patients with CD retrospectively. The Lémann Index was determined at the point of inclusion and at follow-up termination. The Paris definition was used to subdivide patients into early and late CD groups. Results : We included 154 patients, comprising 70 with early CD and 84 with late CD. After follow-up for 17.0 months, more patients experienced a decrease in the Lémann Index (61.4% vs . 42.9%), and fewer patients showed an increase in the Lémann Index (20% vs . 35.7%) in the early compared with the late CD group. Infliximab and other therapies reversed bowel damage to a greater extent in early CD patients than in late CD patients. Twenty-two patients underwent intestinal surgery, involving 5 patients in the early CD group and 17 patients in the late CD group. Three independent predictors of bowel resection were identified: baseline Lémann index ≥ 8.99, disease behavior B1, and history of intestinal surgery. Conclusions : Early intervention within 18 months after CD diagnosis could reverse bowel damage and decrease short-term intestinal resection. Patients with CD with a history of intestinal surgery, and/or a Lémann Index > 8.99 should be treated aggressively and monitored carefully to prevent progressive bowel damage.
Research progress of Crohn's disease related genes

Huan DENG,Yinghui LIU,Pan CAO,Weiguo DONG

DOI: https://doi.org/10.3969/j.issn.1006-5709.2018.05.023

2018-01-01

Abstract:Crohn's disease (CD) is a chronic inflammatory granulomatous disease of the gastrointestinal tract which is associated with multiple genes. This article aims to review the recent advance about related genes of CD, such as NOD2/CARD15,ATG16L1,IRGM,IL-23/TH17 signaling pathways,PTGER4, IBD5 gene loci and PTPN2. NOD2/CARD15,ATG16L1, IRGM, IL-23/TH17 signaling pathways, PTGER4, IBD5 gene loci and PTPN2 are associated with the genetic predisposition of CD. These genes are associated with clinical manifestations,treatment effect and sur-vival rate in CD. These genes lay a theoretical foundation for the research in the pathogenesis of CD and the targeting treatment in related genes.
Progress in Study on Thalidomide for Treatment of Crohn's Disease

XU Pingping,XIAO Yinglian,CHEN Yujun,CHEN Baili,HE Yao,CHEN Minhu,HU Pinjin

DOI: https://doi.org/10.3969/j.issn.1008-7125.2012.09.014

2012-01-01

Abstract:Crohn' s disease(CD) is a chronic non-specific intestinal inflammatory disease and its pathogenesis has not yet been fully clarified.In recent years,with the understanding of involvement of tumor necrosis factor(TNF) -αin the pathogenesis of CD,much attention has been paid on the TNF-αtargeted therapy.Thalidomide has anti-TNF-αeffect and has been used in the treatment of CD,especially refractory CD.This article reviewed the progress in study on thalidomide for the treatment of CD.
[Overview of Diet-Related Study in Crohn's Disease].

Guanwei Li,Jian'an Ren,Jieshou Li

DOI: https://doi.org/10.3760/cma.j.issn.1671-0274.2015.12.031

2015-01-01

Abstract:Crohn's disease (CD) is a chronic inflammatory disorder affecting any part of the digestive tract which relapses and remits throughout the disease course. It occurs in individuals with genetic susceptibility and involves an abnormal response of the immune system to the external environment. Besides, improved hygiene, abuse of antibiotics, westernization of diet with high sugar and fat are thought to be associated with rapidly increasing incidence of CD. Certain components of foods may influence gut inflammation through antigen presentation and alteration of the microflora. This article aims mainly to review diet-related clinical studies to outline its roles in the pathogenesis and progress of disease, and then give some evidence-based suggestions.
Crohn's Disease As the Intestinal Manifestation of Pan-Lymphatic Dysfunction: an Exploratory Proposal Based on Basic and Clinical Data.

Yu-Wei Zhou,Yue Ren,Miao-Miao Lu,Ling-Ling Xu,Wei-Xin Cheng,Meng-Meng Zhang,Lin-Ping Ding,Dong Chen,Jian-Guo Gao,Juan Du,Ci-Liang Jin,Chun-Xiao Chen,Yun-Fei Li,Tao Cheng,Peng-Lei Jiang,Yi-Da Yang,Peng-Xu Qian,Peng-Fei Xu,Xi Jin

DOI: https://doi.org/10.3748/wjg.v30.i1.34

IF: 5.374

2024-01-01

World Journal of Gastroenterology

Abstract:Crohn's disease (CD) is caused by immune, environmental, and genetic factors. It can involve the entire gastrointestinal tract, and although its prevalence is rapidly increasing its etiology remains unclear. Emerging biological and small-molecule drugs have advanced the treatment of CD; however, a considerable proportion of patients are non-responsive to all known drugs. To achieve a breakthrough in this field, innovations that could guide the further development of effective therapies are of utmost urgency. In this review, we first propose the innovative concept of pan-lymphatic dysfunction for the general distribution of lymphatic dysfunction in various diseases, and suggest that CD is the intestinal manifestation of pan-lymphatic dysfunction based on basic and clinical preliminary data. The supporting evidence is fully summarized, including the existence of lymphatic system dysfunction, recognition of the inside-out model, disorders of immune cells, changes in cell plasticity, partial overlap of the underlying mechanisms, and common gut-derived fatty and bile acid metabolism. Another benefit of this novel concept is that it proposes adopting the zebrafish model for studying intestinal diseases, especially CD, as this model is good at presenting and mimicking lymphatic dysfunction. More importantly, the ensuing focus on improving lymphatic function may lead to novel and promising therapeutic strategies for CD.
Advances on Genetic Susceptibility of Crohn's Disease

Qiongyi XIAO,Yunhong LI,Liping DUAN

DOI: https://doi.org/10.3969/j.issn.1008-7125.2009.07.016

2009-01-01

Abstract:Crohn's disease (CD) is a chronic inflammatory granulomatous disease. The incidence rate of CD has increased in recent years, but its etiology and pathogenesis still remain unknown. More and more studies have shown that genetic susceptibility, environmental factor and immunity factor play key roles in the development of CD. This article reviewed the recent advances on genetic susceptibility of CD.
Difficulties in Diagnosis and Treatment of Crohn Disease

Pin-jin Hu

DOI: https://doi.org/10.3760/cma.j.issn.1671-0274.2013.04.001

2013-01-01

Abstract:The incidence of Crohn disease has gradually increased in recent years.The diagnosis and treatment of Crohn disease has gained more and more attention from clinicians.This article is to propose solutions to problems in the diagnosis and treatment of Crohn disease,based on evidence from clinical trials,including the diagnosis,differential diagnosis,management of steroid-refractory disease and anal fistula,and timing of surgery.
Nutritional and dietary strategy in the clinical care of inflammatory bowel disease

Meng-Shu Hsieh,Wen-Hung Hsu,Jiunn-Wei Wang,Yao-Kuang Wang,Huang-Ming Hu,Wei-Kuo Chang,Chih-Yen Chen,Deng-Chyang Wu,Fu-Chen Kuo,Wei-Wen Su

DOI: https://doi.org/10.1016/j.jfma.2019.09.005

IF: 3.871

2020-12-01

Journal of the Formosan Medical Association

Abstract:The incidence and prevalence of inflammatory bowel disease have been increasing for decades and IBD has become a worldwide disease. Epidemiology studies demonstrated higher incidence rates in the more westernized countries. The change of habitual diets in these countries is perceived as the reason for the development of IBD. Besides, molecular biological studies showed some pathogenic substances produced after digestion of daily diet decrease the diversity of intestinal microbiota and cause dysbiosis of microbiome. Then, chronic inflammation occurs in some genetically susceptible subjects and IBD developed. As a result, many researchers started to investigate the potential therapeutic effects of nutrients and dietary intervention on the clinical course and pathogenesis of IBD. Carbohydrates, fats, proteins and fibers are investigated and their molecular roles in the inflammatory process are discovered gradually. The undigested carbohydrates are proved to cause overgrowth of colonic bacteria and inflammation occurs by altering colonic microbiome. ω-3 poly-unsaturated fatty acids are more favored over ω-6 poly-unsaturated fatty acids due to its less pro-inflammatory properties. High fibers produce more short-chain fatty acids in colon and facilitate the diversity of colonic microbiota. Moreover, some dietary interventions were designed and studied with promising results. Low FODMAP is recommended in IBS and is also suggested in patients of IBD with IBS-like symptoms. Specific Carbohydrate Diet was designed for celiac disease at first and is proved to be effective to decrease inflammation and to induce remission by decreasing non-digested carbohydrates into colon. Exclusive Enteral Nutrition has been investigated and is suggested to be the first line of management in pediatric CD in many literatures. Paleolithic diet and semi-vegetarian diet are evaluated and might be beneficial in some clinical settings. These findings are promising but limited to the evidence without high quality level. Some more well-designed studies with randomization and double-blind are needed and the primary endpoints should be more focused on the decrease of inflammation in pathology and mucosal healing in endoscopy instead of relief of the symptoms.

medicine, general & internal
Intestinal stricture in Crohn's disease: A 2020 update

Xiao Xuan Lin,Yun Qiu,Xiao Jun Zhuang,Fen Liu,Xiao Min Wu,Min Hu Chen,Ren Mao

DOI: https://doi.org/10.1111/1751-2980.13022

2021-01-01

Journal of Digestive Diseases

Abstract:Crohn's disease (CD) is a chronic and relapsing-remitting inflammatory disorder of the gastrointestinal tract. Approximately 70% of patients inevitably develop fibrosis-associated intestinal stricture after 10 years of CD diagnosis, which seriously affects their quality of life. Current therapies play limited role in preventing or reversing the process of fibrosis and no specific anti-fibrotic therapy is yet available. Nearly half of patients thus have no alternative but to receive surgery. The potential mechanisms of intestinal fibrosis remain poorly understood; extracellular matrix remodeling, aberrant immune response, intestinal microbiome imbalance and creeping fat might exert fundamental influences on the multiple physiological and pathophysiological processes. Recently, the emerging new diagnostic techniques have markedly promoted an accurate assessment of intestinal stricture by distinguishing fibrosis from inflammation, which is crucial for guiding treatment and predicting prognosis. In this review, we concisely summarized the key studies published in the year 2020 covering pathogenesis, diagnostic modalities, and therapeutic strategy of intestinal stricture. A comprehensive and timely review of the updated researches in intestinal stricture could provide insight to further elucidate its pathogenesis and identify novel drug targets with anti-fibrotic potentiality.
[Research advance on the interaction between gut microbes and cytokines in inflammatory bowel disease]

Xinyu Lu,Shuli Zhang,Xiaofeng Li,Haiyan Li

Abstract:Dysregulation of interaction between the gut microbiota and the host immune system leads to the development of chronic inflammation, such as inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC). Numerous studies have shown that the host-microbiota of IBD can directly or indirectly affect the homeostasis of the immune system. Furthermore, the balance between pro-inflammatory and anti-inflammatory cytokines involves in maintaining a healthy microbiota community and enhances epithelial barrier functions. Understanding the interactions between gut microbiota and cytokines (IL-10, IL-17, IL-18, TNF-α) provides crucial insights into the pathogenesis of inflammatory bowel disease.
Primary studies on comprehensive clinical efficacy of Infliximab in Crohn's disease

Xiuli ZHU,Qiaomin WANG,Yong JIA,Zhengxiang WU,Qiuxia JIANG,Jiajia WANG

DOI: https://doi.org/10.3969/j.issn.1006-5709.2017.04.015

2017-01-01

Abstract:Objective To investigate the effect of Infliximab (IFX) on clinical symptoms,mucosal healing,nutritional status and mental status of patients with Crohn's disease (CD).Methods The clinical data of CD patients who received IFX treatment from Aug.2011 to Oct.2016 were collected,including laboratory indexes,CDAI,SES-CD,NRS-2002,PG-SGA,SDS,SAS and IBD-Q.Results The clinical remission rates were 68.2％ (15/22),100％ (22/ 22) at 0,6 weeks after treatment,respectively.88.9％ (16/18) of the patients maintained clinical remission at 14 to 30 weeks,100％ (10/10) maintained clinical remission at 38 to 54 weeks.The deep remission rates was 16.7％ (3/ 18) at 14 to 30 weeks,80.0％ (8/10) at 38 to 54 weeks.According to the PG-SGA score,81.8％ (18/22) were severe malnutrition before treatment,60.0％ (6/10) of the patients had good nutrition and no nutritional risk at 38 to 54weeks.Before treatment,40.9％ (9/22) patients were associated with anxiety,54.5％ (12/22) patients with depression.At 6 weeks after treatment,SAS and SDS scores were significantly lower than before treatment (P ＜0.05).At 14to 54 weeks,the patients had no depression and anxiety,while the IBD-Q score was significantly increased after treatment(P ＜0.05).Conclusion IFX can induce and maintain clinical remission in patients with CD early.Long-term treatment can induce and maintain deep remission.In CD patients,the incidence of depression and anxiety is high and the quality of life is low.Early clinical remissiou can significantly improve the patients mental state and quality of life.
Research progress of mesenchymal stromal cells therapy for patients with inflammatory bowel disease

Ping Lan,Xuanhui Liu,Xianrui Wu

DOI: https://doi.org/10.3760/cma.j.issn.1673-9752.2018.09.003

2018-01-01

Abstract:The inflammatory bowel disease (IBD) includes Crohn's disease and ulcerative colitis.The incidence of IBD is rising on a yearly basis in China,followed by an increased number of patients who suffer from the complications.Medicines and surgical treatment are the major maneuver in the management of patients with IBD.Recently,mesenehymal stromal cells MSCs were found to exert powerful immunomodulatory effects,which suggest the possibility of an alternative treatment for patients with IBD.In this article,the most recent literatures in this field will be reviewed combining with our own clinical experiences.The functions of MSCs,the pathogenesis of IBD and research situation of MSCs therapy for patients with IBD will be discussed.
Clinical Treatment Strategy of Crohn' s Disease

Junzhang ZHAO,Ge WANG,Bing XIA

DOI: https://doi.org/10.3969/j.issn.1008-7125.2012.12.006

2012-01-01

Abstract:With increasing understanding of the pathogenesis of Crohn's disease (CD), the progress in the biologic therapy and the proposal of mucosal healing as the endpoint of treatment, treatment of CD has changed radically. This article reviewed the progress in treatment of CD in accordance with stage, severity, localization of the disease and special populations.
Research status of dietary behavior intervention on patients with inflammatory bowel disease

Li Ji,Jiao-jiao Bai

DOI: https://doi.org/10.14725/gjanp.v3n1.a1449

2016-01-01

Abstract:Inflammatory bowel disease is one of the modern refractory diseases, characterized by chronic, debilitating condition. The occurrence development of inflammatory bowel disease is not only related to the kind of food intake, but also associated with capacity. Good eating behavior can guarantee the reasonable dietary structure and balance nutrition intake to promote health. As one of the comprehensive treatment, diet therapy is the key to control the inflammatory bowel disease. This research reviewed the current nursing situation of dietary behavior in patients with inflammatory bowel disease in order to provide the basis for clinical practice.

Research progress of early intervention in Crohn′s disease

Advances in early diagnosis and treatment of Crohn's disease

Research progress of early clinical diagnosis of Crohn′s disease

Anti-cytokine Therapy and Small Molecule Agents for the Treatment of Inflammatory Bowel Disease

Research progress of metabonomics and nutritional intervention in Crohn's disease

Research progress on acupuncture and moxibustion for treatment of Crohn's disease based on the regulation of innate immunity

Pay Attention to Early Diagnosis and Management of Crohn’s Disease

Efficacy of Early Intervention on the Bowel Damage and Intestinal Surgery of Crohn’s Disease, Based on the Lémann Index

Research progress of Crohn's disease related genes

Progress in Study on Thalidomide for Treatment of Crohn's Disease

[Overview of Diet-Related Study in Crohn's Disease].

Crohn's Disease As the Intestinal Manifestation of Pan-Lymphatic Dysfunction: an Exploratory Proposal Based on Basic and Clinical Data.

Advances on Genetic Susceptibility of Crohn's Disease

Difficulties in Diagnosis and Treatment of Crohn Disease

Nutritional and dietary strategy in the clinical care of inflammatory bowel disease

Intestinal stricture in Crohn's disease: A 2020 update

[Research advance on the interaction between gut microbes and cytokines in inflammatory bowel disease]

Primary studies on comprehensive clinical efficacy of Infliximab in Crohn's disease

Research progress of mesenchymal stromal cells therapy for patients with inflammatory bowel disease

Clinical Treatment Strategy of Crohn' s Disease

Research status of dietary behavior intervention on patients with inflammatory bowel disease